NUS Researchers Develop Novel Microneedle Patch
Dr. Kang Lifeng and a research team from the Department of Pharmacy at the National University of Singapore (NUS) Faculty of Science have achieved a significant breakthrough in painless drug delivery with the development of a fast-acting microneedles patch. This innovative patch allows for the quick and comfortable delivery of collagen to the dermis layer of the skin.
The microneedles patch consists of small polymeric needles attached to an adhesive patch. These needles are capable of encapsulating lidocaine, a common painkiller, or collagen. When applied to the skin, the microneedles painlessly and rapidly deliver the drug or collagen, providing a seamless experience for the user.
This user-friendly drug delivery system holds great potential for use in clinics and home care settings, allowing for non-invasive administration of painkillers to patients. It is particularly advantageous for individuals with conditions such as diabetes and cancer, as well as for cosmetic and skincare purposes, as it efficiently delivers collagen to the deeper layers of the skin.
With needle shafts measuring around 600 micro-meters in length, the patch can deliver lidocaine within just five minutes of application, causing no discernible discomfort to the skin. Additionally, the patch's size can be easily adjusted to accommodate different dosages of the drug. This innovative patch also shows promise in pediatric medicine.
The microneedles patch incorporates a reservoir system that acts as channels, allowing drugs to be encapsulated in backing layers. This prevents premature closure of the microneedles' miniature pores, facilitating continuous drug permeation into the skin.
By enhancing the amount of lidocaine that permeates through the skin, this patch ensures ease of application while reducing the likelihood of skin irritation for patients.
The research team intends to conduct clinical trials of the painkiller patch to further assess its effectiveness in various clinical applications. To protect their invention, the researchers have filed a patent through the NUS Industry Liaison Office, which operates as part of NUS Enterprise.
ise.
